On August 6, 2024, Clene Inc. announced the submission of new biomarker and clinical efficacy data for CNM-Au8 to the U.S. Food and Drug Administration (FDA) in support of its treatment for amyotrophic lateral sclerosis (ALS). The announcement was made through a press release, which is now filed as Exhibit 99.2 with the company's Current Report on Form 8-K. Additionally, Clene Inc. updated its corporate presentation on its investor relations website, which is furnished as Exhibit 99.1 in the same report. The company has indicated that future updates to the corporate presentation may be disseminated through its website without filing or furnishing a Current Report on Form 8-K to alert investors.

On August 6, 2024, Clene Inc. announced the submission of new biomarker and clinical efficacy data for CNM-Au8 to the U.S. Food and Drug Administration (FDA) in support of its treatment for amyotrophic lateral sclerosis (ALS). The announcement was made through a press release, which is now filed as Exhibit 99.2 with the company's Current Report on Form 8-K. Additionally, Clene Inc. updated its corporate presentation on its investor relations website, which is furnished as Exhibit 99.1 in the same report. The company has indicated that future updates to the corporate presentation may be disseminated through its website without filing or furnishing a Current Report on Form 8-K to alert investors.